Among advanced GC patients receiving anti-PD-1 therapy, responders exhibited a higher mean percentage of PD-1+ cells in TEM (P = 0.017) than non-responders, which were associated with longer PFS. This evidence concerns the gene PDCD1 and gastric cancer.